http://www.fiercepharma.com/story/lilly-bets-new-insulin-products-180m-plant-addition/2013-04-02?utm_medium=nl&utm_source=internal

"Lilly is making significant investments to support our current portfolio of diabetes medicines," said Enrique Conterno, president of Lilly Diabetes. "We are also continuing to search for new and better treatment options..."

Lilly sales were hit hard last year after it lost patent protection on the antipsychotic Zyprexa. It loses patent protection on its insulin Humalog in a couple of months and later this year on the blockbuster antidepressant Cymbalta. That will keep pressure on the company to come through with new products.

Oncostat